Peer Review History
Original SubmissionOctober 3, 2021 |
---|
PONE-D-21-31763CRISPR/Cas9-mediated targeted mutagenesis of GmTRP19 increasing susceptibility to Phytophthora sojae in soybeanPLOS ONE Dear Dr. Fan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that this study has scientific merit but the current manuscript does not fully meet PLOS ONE’s publication criteria. The reviewers pointed out several aspects such as the writing, statistics, and concerns about CRISPR specificity and additional phenotypes that need to be further clarified. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Dec 17 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Hao-Xun Chang, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service. Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free. Upon resubmission, please provide the following: ● The name of the colleague or the details of the professional service that edited your manuscript ● A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file) ● A clean copy of the edited manuscript (uploaded as the new *manuscript* file) 3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.
In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: N/A Reviewer #3: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: 1. The authors used CRISPR/Cas9 based genome editing to knock out a soybean TCP domain-containing gene Glyma05g03610 to study its function. They designed a genome editing DNA construct targeting two sites around the critical TCP domain of the gene, transformed Williams 82 and obtained up to 14 T1 lines with either of the two sites edited (according to Table 1). But they either failed to characterize all the edited lines in detail or did not report the results. For example, the chromatographs in S3 Fig can be easily replaced with conclusive sequences of the edited events by sequencing a few clones of the PCR fragments amplified from the target region. They can also carry the heterozygous events to T2 generation to obtain transgene-free homozygous mutants to study their phenotypical effects. In other words, the authors achieved the most important part of the study by obtaining multiple edited events but failed to do follow-up study on them to get more comprehensive results. 2. Although the authors summarized in the Introduction and Discussion that TCP transcription factors can function in various aspects such as leaf development [37], leaf morphogenesis [2], leaf senescence [20], trichome development [30, 55], flower development [13, 56, 57], circadian clock [58], hormone signaling [28, 59, 60], response to varies stresses [35, 60–63], and plant defense [22, 33], they assumed the Glyma05g03610 gene in this played a role in plant defense and only did a simple infection experiment using only one mutant line. With as many as 14 edited lines in hands, the authors should evaluate all aspects of the edited plants and compare multiple lines at multiple stages to wild type controls to get a more convincing conclusion about the function of the gene. If possible, they should also get molecular and/or biochemical evidence to support their conclusion. 3. What is the “R” in GmTRP19 standing for since all the other related genes are named as TCP. It was first described on page 3 lines 8-11 “In a previous study, GmTRP19 (Glyma05g03610, a TCP transcription factor related to P. sojae) was significantly induced after infection with P. sojae among several soybean near isogenic lines revealed by comparative transcriptomics [38].” But it seems that neither the term of GmTRP19 or Glyma05g03610 is listed in the reference. 4. The manuscript should be carefully checked and edited before submitting. There are numerous errors or improper use of English such as those listed below. Page 1 line 14: transformation were used Page 2 line 4: causing obvious increasing Page 2 line 4: transgenic element of the CRISPR/Cas9 vector, which suggesting directions for Page 2 lines 12-18 should be placed after the general introduction of TCP on page 3. The entire Introduction should be better organized. Page 4 line 9: auxin-induced related genes Page 5 line 6: expression of LOX2 gene and reduced the production of JA, Page 5 line 13: function of this gene resistance to P. sojae. Page 5 line 15: and maintained consistent mutation types Page 5 line 16: A certain amount of 2-bp deletion trp19 mutants Page 6 line 11: P. sojae race 1 was kindly provided by professor zhang? Page 7 line 1: Having demonstrated that the Page 7 line 6: the Glycine max U6 promoter (GmU6) within its T-DNA region: The Cas9 is not expressed by the U6 promoter. Page 7 line 7: The bar/basta gene: bar is the Phosphinothricin N-acetyltransferase gene of Streptomyces hygroscopicus. Phosphinothricin is the active component of commercial herbicide Basta. Page 7 line 10: The GmTRP19-CRISPR/Cas9 positive plasmids Page 8 line 5: Simultaneously, we sought to: Transgene-free mutants can only be produced in T1 or T2 progenies through genetic segregation. Page 8 line 10: potential off-target sites effecting on phenotype, Page 8 line 12: off-target sites for each guide would be selected, Page 8 lines 15-16: to determine whether there were presence of the off-target sites in the amplicon by sequenced. Page 8 line 18: The “transgene-clean” trp19 mutant lines: Transgene-free Page 9 line 6: the significance differences Page 10 line 2: targeted PAM in the exon of GmTRP19 (Fig 1). The CRISPR/Cas9 construct were Page 10 lines 12-13: homozygous for null alleles of GmTRP19 and two types of mutations at target site GmTRP19-SP1 (2-bp deletion and 1-bp deletion) were detected (Fig 2A, B).: The description is incomplete and not clear. There were homozygous mutant plants detected in three trp19-SP1 T1 lines and also in three trp19-SP2 T1 lines according to Table 1. A total of 14 T1 lines had heterozygous mutant plants. What happened in them? Indels in the target sequences of these homozygous mutant plants should be listed. Indels in the target sequences of the heterozygous mutant plants should also be experimentally determined and then listed. Page 12 lines 18-19: and the part of Cas9 coding sequence in the T-DNA of CRISPR/Cas9 vector was also spanned. Page 13 line 8: type soybean plant. Labels 1–14, individual mutant lines. Should “lines” be plants? Page 13 line 10: T-DNA regions of CRISPR/Cas9 vector. Page 13 line 17: and all of their Page 15 line 2: is an important food and economic crops Page 15 line 17: shortened internodes use of the CRISPR/Cas9 system in soybean Page 15 line 18: obtained E1 gene mutants using CRISPR/Cas9 and soybean transformation, Page 16 lines 1-2: GmTRP19 by CRISPR/Cas9 ge 1 nome editing approach without any transgenic element of the CRISPR/Cas9 vector, which quickly became a powerful resource for soybean Page 16 line 5: Having demonstrated that Page 16 line 8: which suggesting directions for the breeding or genetic engineering of Page 30 line 4: S2 Fig. The basic architecture of the constructs Page 30 line 6: promoter. sgRNA, small guide-RNA. S5 Fig. The trp19-SP1-T1#02.03 (2-bp deletion) and trp19-SP1-T1#02.08 (2-bp deletion) are the same sequence since the two plants are derived from the same T1 line. No need to list the same sequence twice. Where is the (1-bp deletion) line or the 14-bp deletion line? S1 Table. GmActin primers? Reviewer #2: Manuscript Number: PONE-D-21-31763 Full Title: CRISPR/Cas9-mediated targeted mutagenesis of GmTRP19 increasing susceptibility to Phytophthora sojae in soybean. Opinion: The article proposed to study the function of the GmTRP19 gene in soybean plants, which is expected to be involved in defense against Phytophthora sojae. For this, they used the CRISPR/Cas9 gene editing system to cause an interruption in the expression of GmTRP19 gene. Plants with the edited gene showed an increase in susceptibility to the phytopathogen. So they concluded that directly or indirectly this gene regulates the resistance to P. sojae in soybean. The article also shows the usefulness of the CRISPR system to generate edited plants, nonetheless non-GMO, which avoids the long and costly process of deregulation. It would be interesting to explore the possible positive effect of the expression of that gene in soybean plants, and instead of interrupting its expression, as done here, increase its expression, and thus obtain a product with an important agronomic characteristic, and at the same time corroborate with the answer obtained at this stage of the work. The article must be published as is. Reviewer #3: The research article titled “CRISPR/Cas9-mediated targeted mutagenesis of GmTRP19 increasing susceptibility to Phytophthora sojae in soybean” explored the role of a plant-specific transcription factor in soybean disease resistance to an important crop pathogen, Phytophthora sojae. The manuscript contains a number of grammatical errors, though the content and concepts presented by the authors are logical and easy to follow. In addition, the molecular work is convincing that the CRISPR/Cas9 constructs successfully created mutations in their target gene, that some lines were homozygous for the mutations, and that some lines also lacked the genetic markers and can accurately be described as “transgene-free” mutants. Unfortunately, I have multiple concerns that prevent the manuscript from being acceptable for publication at this time. First, there is no data presented to support the claim that there were no off-target effects from their CRISPR/Cas9 activity. The authors claim there are no off-target effects, yet only provide a supplementary table listing “number of plants with mutations” in off target sites, filled with zeros. The authors describe using the CRISPR-P analysis program, which provides scores based on strength of sequence alignment with a CRISPR construct. The authors ought to describe what threshold they used to identify putative “off-target” candidates, and they also ought to provide some chromatograms to show that these putative off-target sites were not mutated by the CRISPR constructs. Second, I don’t think the authors explore enough phenotypes of their mutants. The authors acknowledge at many points in the manuscript that this class of transcription factor play a wide range of roles in growth, development, flowering, circadian rhythm, etc. But, the authors only present one phenotype – susceptibility to 1 isolate of P. sojae. Therefore, the increased susceptibility to P. sojae could be one of many phenotypes of these mutant lines, which could compromise the conclusion that GmTRP19 has a direct role in resistance to P. sojae. Additionally, the phenotype that the authors do test are only observational, with no numeric data or statistics to suppor the conclusion of increased susceptibility in the mutants. If the authors address these concerns, it could be re-considered for publication in PLOS One. Specific Comments: Page 2, Line 15: Remove “the” before “conserved domains” Page 4, Line 3: What is the FT-FD complex. Please list in full before using an abbreviation. Page 4, Line 4: What is the AP1 gene, and what is the relevance of AtTCP12 and AtTCP18 binding to it? Page 4, Line 17: Hyaloperonospora arabidopsidis is not a gram-negative bacteria. It is an oomycete. Please correct. Page 5, Line 9: Remove “related to P. sojae”. You describe the connection between the gene and P. sojae later in the sentence. Page 5, Line 18: Remove “the” before “resistance”. There is no singular resistance to P. sojae – there is single, R-gene mediated resistance, and partial resistance (Dorrance, 2018 doi.org/10.1080/07060661.2018.1445127). The GmTPS19 gene is not an R-gene. Page 6, line 6: Williams 82 has high partial resistance to P. sojae, but only 1 R-gene mediating robust resistance to specific pathotypes of P. sojae (Dorrance, 2018). Page 6, line 11: Capitalize “Professor Zhang”. Page 8, line 6: What is a PAT/Bar “test strip”? Did you spray these plants with gufosinate? Did you do PCR to detect the presence / absence of this gene? Did you get strips from a company? If so, where? More detail needed here for reproducibility. Page 8, line 12: “Two off-target sites for each guide would be selected” does this mean there were 2 off target sites detected by CRISPR-P analysis? Or only 2 were selected for analysis of off-target effects? There’s a big difference, please clarify. Page 10, lines 7-8: Please clarify the language here a bit. You list two numbers and use “respectively”, but don’t list both conditions. Please change to something like this “…had heterozygous mutations at the first (SP1) and second (SP2) target sites, respectively (S3 Fig in S1 File)”. Page 10, line 16: Please don’t use “PTCs” as an abbreviation. This is unnecessary. Page 12, lines 8-9: How “likely” were these two off-target sites predicted to be affected? How many other off-target sites were identified at a lower “likelihood”? Can you provide the results of the CRISPR-P analysis in the supplemental files, or list here in some form? Page 12, lines 12-13: “no mutations were observed” yet the data to support this is just a table with 0’s listed. Please provide the chromatograms to show evidence that there were no off-target effects on DNA sequence. Page 13, Line 17: “all of their…” all of their what? I think there is a word missing here. Or perhaps “their” is meant to be “them”? Figure 4: These soybeans do not look like they are growing in vermiculite, as described throughout the manuscript. Explain. Page 15, lines 15-19: This brings up a great point. Did any of your GmTRP19 mutants display any other phenotypes besides increased sensitivity to P. sojae? Were there any developmental phenotypes (delayed germinating, effects on plant height, flowering, etc.)? Page 16, line 4: What makes GmTRP19 a “new” member of this family? Page 16, lines 5-9: This entire sentence is an incomplete sentence. Authors could remove “Having demonstrated that”, to make it complete. A few examples of improper grammar. Many others throughout. PLOS One does not copyedit accepted manuscripts. • “We obtained a novel type of mutations” • “which suggesting” • “this gene resistance to P. sojae” • “exhibited more sensitive to P. sojae” • “All of three types” • “an important food and economic crops” [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 1 |
PONE-D-21-31763R1 CRISPR/Cas9-mediated targeted mutagenesis of GmTCP19L increasing susceptibility to Phytophthora sojae in soybean Dear Dr. Fan, Thank you for re-submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit for publication and we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Apr 09 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Hao-Xun Chang, Ph.D. Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. ================================== Additional Editor Comments: The manuscript has been greatly improved in clarity, but some descriptions and methods still need minor revisions and additional details. Page 2 line 1. Delete (P. sojae) Page 2 line 4. The Abstract should be revised. If the authors already known that GmTCP19L controlling soybean resistance to P. sojae, there will be no need for the rest of study presented in the manuscript. The sentence here should be the background, not the conclusion. Description such as “and generated targeted mutants of GmTCP19L gene, which was previously related to involve in soybean responses to P. sojae” would make more sense. Page 2 line 10. The authors emphasized multiple times throughout the manuscript regarding the mutants without "any transgenic elements." This is a bold statement as the authors only detect BAR and a PCR fragment of Cas9 vector. In other words, if there is any other part of vector elements remained in the mutant genome, the methods will have no capability of detecting them. Therefore, I suggest the authors to revise these statements in a conserved way, e.g. the BAR and Cas9 sequences were undetectable using strip and PCR methods, respectively. Others: Page 6 line 1, Page 9 line 6, Page 10 line 12, Page 14 line 15 (Figure 4 title), Page 15 line 6, Page 20 line 12 etc. Page 2 line 14. TCP should be spell-out for clarity especially in the every beginning of the text. Page 3 line 2. Is “shown” to Page 3 line 4. classified “into” Class I Page 3 line 9. Italize cis- Page 3 line 15. Have been found, “and” most of which Page 3 line 18 to Page 4 line 3. This is a long sentence with many information. Please simplify or separate it. Page 4 line 14. No need for (BR) because it is not mentioned later on. Page 4 line 19 to Page 5 line 1. Please double confirm the meaning of this sentence. It reads that two pathogens target TCP to enhance disease resistance…Would the pathogens do these functions against themselves? Page 5 line 10. The authors used the W82a1v1 names throughout the manuscript. However, the popular and common names of soybean genes are already based on the W82a2v1 version, or even a4v1 version. Please revise the name or at least provide W82a2v1 names side-by-side. Others: Page 7 line 2, Figure 3 etc. Please also confirm the name used in the phylogentic tree, it seems to be the a2v1 name. Page 5 line 14. Arabidopsis, “and” this Page 5 line 16. In “the” soybean cultivar Page 5 line 18. “with” short deletions Page 6 line 4. soybean resistance to P. sojae. Page 6 line 10. “high resistance to P. sojae” is not a specific or scientific description. How high is high? Please be specific, e.g. W82 carries Rps-1k? or what do the authors mean for high? Page 7 line 9-12. Please provide the vector plot with clear locations of primers, the BAR resistance gene, the cloning regions for GmTCP19L, and the detection region for Cas9. Page 7 line 15. More details needed for tri-parental mating. Page 8 line 8-9. Delete the parenthesis. Frameshift mutation is clear enough. Page 8 line 10-13. Please specify the length or region of BAR detection and Cas9 amplicon. Page 9 line 17-18. More details of the methods are needed. How as the P. sojae quantified? Disease severity? Counting sporangia? qPCR? In addition, what was the statistical method? Page 10 line 4. One gram Page 10 line 7. Which part of results were analyzed using “multiple pairwise comparison”? In addition, was the assumption of t test checked? Please specify. Page 11 line 20. Replace “. Simultaneously” to “; meanwhile,” Page 14 line 1. Please provide figure legend for Figure 3. Please verify the version of soybean gene name. Page 15 line 5. In response to Page 15 line 6-7. Are these two T1 lines, tcp19l-SP1-T1 7 (2-bp deletion), tcp19l-SP1-T2), identical to “tcp19l-SP1-T1#02.03 and tcp19l-SP1-T1#02.08”? Or which is which? Please clarify. Page 16 line -2. Methods for qualification needed. Page 16 line 9. Please provide figure legend for Figure 5. Page 16 line 15 to Page 17 line 3. If this is the quantification method, please move to M&M, and specify the primers and provide methods e.g. construction of standard curve? for details. Page 18 line 16 to Page 19 line 1. Page 18 line 12. RNA-Seq Page 19 line 20 to Page 20 line 1. Please provide previse literature for supporting ROS involves in P. sojae resistance. Page 20 line 11. Delete Now. In Figure 5 and 6, please clarify which lineage does the tcp19l-SP1-T2 and tcp19l-SP1-T3 from? Are they 2-bp or 1-bp deletion mutants? Are they progenies of tcp19l-SP1-T1#02.03 and tcp19l-SP1-T1#02.08? Have different mutant lines/lineage being tested for resistance? Please note if only one mutant lineage was used in pathogenicity test, the results may not be convincing. If different mutant lineage, e.g. 2-bp and 1-bp, were tested and the results were consistent, the conclusion will be more reliable. In addition to these editorial suggestions, the reviewers would like to know more about the phenotypes of 2-bp or 1-bp deletion mutants, and/or tcp19l-SP1-T1#02.03 and tcp19l-SP1-T1#02.08. The reviewers’ opinion is highly respected because if there are other phenotypic defects, the damping-off may be a side-effect due to other genetic problems instead of purely disease susceptibility. Your feedback in the discussion included several literatures mostly based on Arabidopsis (Page 18 line 16-20), but not direct observation on your T0, T1, T2, or T3 soybean mutants. Therefore, I would like to invite you to provide more details for the final editorial and content improvement. Reviewers' comments: The authors have addressed all but 1 concern from previous review. As I noted, and as noted by the other reviewer, and acknowledged by the authors themselves, mutating a transcription factor can have broad effects. Yet, the only phenotype examined was "resistance to P. sojae". While the authors acknowledge that they intend to look for other phenotypes in follow up work, it would be beneficial here. Only a few small remaining comments that, if addressed, make it suitable for publication. The grammar is improved, though some issues are still present. Page 11, lines 7-8: Here, GmTCP19L-SP1 and GmTCP19L-SP2 are described as “target sites”. Yet an entire section on page 8 lines 14-20 is dedicated to the description of “off-target sites” called the same thing. Please clarify what is meant by “off-target sites” throughout the manuscript. I believe you designed GmTCP19L-SP1 and GmTCP19L-SP2 as “target sites”, and then looked to see if either of them could have off-target activity. Remove the red dashed circles from Figure 5. Provide units / description for Y-axis in Figure 6B. What does “Accumulation” represent? Number of zoospores re-isolated? Quantity of P. sojae DNA per µg of plant DNA? |
Revision 2 |
CRISPR/Cas9-mediated targeted mutagenesis of GmTCP19L increasing susceptibility to Phytophthora sojae in soybean PONE-D-21-31763R2 Dear Dr. Fan, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Hao-Xun Chang, Ph.D. Academic Editor PLOS ONE |
Formally Accepted |
PONE-D-21-31763R2 CRISPR/Cas9-mediated targeted mutagenesis of GmTCP19L increasing susceptibility to Phytophthora sojae in soybean Dear Dr. Fan: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Hao-Xun Chang Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .